Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review

Acta Otorrinolaringol Esp (Engl Ed). 2018 Jul-Aug;69(4):208-213. doi: 10.1016/j.otorri.2017.07.001. Epub 2017 Oct 20.
[Article in English, Spanish]

Abstract

Introduction and objectives: Olfactory neuroblastoma (ONB) is a rare entity that constitutes less than 5% of nasosinusal malignancies. Mainstream treatment consists in surgical resection+/-adjuvant radiotherapy. By exposing results observed with apparition of new therapeutic options as neoadjuvant chemotherapy, the objective is to evaluate a series and a review of the current literature.

Methods: A retrospective review was conducted including patients diagnosed and followed-up for ONB from 2008 to 2015 in our institution.

Results: 9 patients were included. Mean follow-up of 52.5 months (range 10-107). Kadish stage: A, 1 patient (11.1%) treated with endoscopic surgery; B, 2 patients (22.2%) treated with endoscopic surgery (one of them received adjuvant radiotherapy); C, 6 patients (66.7%), 4 patients presented intracranial extension and were treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. The other 2 patients presented isolated orbital extension, treated with radical surgery (endoscopic or craniofacial resection) plus radiotherapy. The 5-year disease free and overall survival observed was 88.9%.

Conclusion: Neoadjuvant chemotherapy could be an effective treatment for tumor reduction, improving surgical resection and reducing its complications.

Keywords: Adjuvant radiotherapy; Endoscopic surgery; Estesioneuroblastoma; Esthesioneuroblastoma; Neoadjuvant chemotherapy; Neuroblastoma olfatorio; Olfactory neuroblastoma; Quimioterapia neoadyuvante; Radioterapia adyuvante; Resección endoscópica.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Chemotherapy, Adjuvant
  • Esthesioneuroblastoma, Olfactory / drug therapy*
  • Esthesioneuroblastoma, Olfactory / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Nasal Cavity*
  • Neoadjuvant Therapy
  • Nose Neoplasms / drug therapy*
  • Nose Neoplasms / surgery*
  • Retrospective Studies